期刊文献+

以泰素帝为主联合化疗治疗晚期乳腺癌87例临床观察 被引量:1

原文传递
导出
摘要 目的观察以泰素帝为主联合化疗治疗晚期乳腺癌患者的疗效及毒副反应。方法对87例晚期乳腺癌患者施以泰素帝+顺铂(TP)或泰素帝+卡铂(TC)方案化疗6~8个疗程。结果 CR 5例;PR 71例;SD 5例;PD 6例,总有效率93.1%。最常见的毒副反应为骨髓抑制,Ⅲ~Ⅳ度白细胞下降占15%,Ⅲ度血小板下降占6.5%,非血液学毒性轻微。结论以泰素帝为主联合化疗治疗晚期乳腺癌有较好的疗效,毒性反应可以耐受。
作者 胡传杏子
出处 《临床急诊杂志》 CAS 2007年第6期358-359,共2页 Journal of Clinical Emergency
  • 相关文献

参考文献8

  • 1SUN YAN, LI WEILIAN, GUANG ZHONGZHEN. Taxotere phase Ⅱ study in Chain[J]. J New Drug 1998,7(3).
  • 2KAUFMAN SCHRIJVERS D, et al. Coping with docetaxel(Taxotere) [J]. Ann Oncol 1993 ,4:610.
  • 3HAINSWORTH JD,GRECO FA. Phase I Trial of weekly docetaxel in Patients with advanced, refractory cancer[ J ]. Breast Res Treat 1997 ,46 : 234a.
  • 4GELMON K. The taxoids: paclitaxel and docetaxel [ J ]. Lanet, 1994,344 : 1267.
  • 5ANDREU JM,DIAZ JF,GIL R,et al. Solution structure of TAXO- TERE - induced microtubules to 3-nm resolution. The change in portofilament number is linked to the binding of the Taxol side chain[J]. J Biol Chem, 1994 ,269:31785.
  • 6KELLAND LR, ABEL G. Comparative in vitro cytotoxicity of Taxol and TAXOTERE against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines [ J ]. Cancer Chemothe Pharmacol, 1992,30:444.
  • 7VOGEL M, HILSENBECK SG, DEPENBROCK H, et al. Pre-clinical activity of TAXOTERE ( RP 56976, NSC 628503 ) against freshly explanted clonogenic human tumor cells:comparison with Taxol and conventional antineoplastic agents [ J]. Eur J Cancer, 1993,29A :2009.
  • 8HILL BT,WHELAN RDH SHELLARD SA,et al. Differential cytotoxic effects of docetaxl in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro[ J ]. Invest New Druges, 1994,12:169.

同被引文献8

  • 1代志军,王西京,仵文英,刘小旭,纪宗正,康华峰,薛锋杰,薛兴欢.3种新辅助化疗方案治疗乳腺癌的药物经济学比较[J].医药导报,2007,26(5):555-558. 被引量:4
  • 2RICHARD H B,DUSAN K.Phase 1b dosefinding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer[J].Breast Cancer Res Treat,2012,135(1):241-252.
  • 3JUNG M,KOO J S.Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy[J].Plos One,2012,7(9):e45127.
  • 4JOHN M,HINKE A,STAUCH M.Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclinesa phase II multipractice study[J].BMC Cancer,2012,12(1):165.
  • 5HAKANSON M,KOBEL S.Controlled breast cancer microarrays for the deconvolution of cellular multilayering and density effects upon drug responses[J].Plos One,2012,7(6):e40141.
  • 6MARTIN J,MAGNINO F.Hint2,a mitochondrial apoptotic sensitizer downregulated in hepatocellular carcinoma[J].Gastroenterology,2006,130(7):2179-2188.
  • 7陈莲芳.乳腺癌药物治疗进展[J].河北医学,2008,14(8):1000-1002. 被引量:1
  • 8白晓蓉,梁玉荣,杨碎胜.泰素帝在乳腺癌新辅助化疗中的可行性[J].甘肃医药,2009,28(6):435-436. 被引量:1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部